# A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat

Source: https://nuclide.cc/trials/nct06040099/  
Nuclide record `nct06040099` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE is a phase 2 interventional study registered as NCT06040099 by AstraZeneca, with 58 participants enrolled, started 2024-02-13 and due to reach its primary completion in 2026-07-01. Interventions recorded: Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: EMERALD-Y90
- Tags: ctgov-ingest
- Registry id: NCT06040099
- Phase: 2
- Setting: Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
- Sponsor: AstraZeneca
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT06040099: https://clinicaltrials.gov/study/NCT06040099

## Connected records

- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/)
- drugs: [Durvalumab](https://nuclide.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://nuclide.cc/companies/astrazeneca/)
- fronts: [Radioembolisation](https://nuclide.cc/fronts/f-radioembolisation/)
- pairings: [Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/)

---
JSON: https://nuclide.cc/api/v1/entities/nct06040099.json